Oncolytics Biotech says new pelareorep cancer immunotherapy method-of-use patent issues in several countries
ONCY•Oncolytics Biotech disclosed that method-of-use patents covering pelareorep as a cancer immunotherapy have issued in several countries. U.S. issuance is expected soon, and covered uses could receive protection into the late 2040s, subject to final claims and terms.
1. Patent protection
Oncolytics Biotech said method-of-use patents covering pelareorep as an immunotherapy for cancer have issued in several countries. U.S. issuance is expected soon, with protection for covered uses planned to extend into the late 2040s, subject to final claims and terms.
2. Other patent filings
The company said manufacturing patent protection runs through 2044 and three patent application families are pending, including additional method-of-use filings. One pending U.S. application is slated for Track One review this quarter. Oncolytics is also developing a modified “next generation” pelareorep to support a future composition-of-matter patent with a potential 20-year term from filing.
